Cargando...

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation

Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMJ Case Rep
Main Authors: Niwa, Hideyuki, Nakahara, Yoshiro, Sasaki, Jiichiro, Masuda, Noriyuki
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Case Reports 2018
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5990104/
https://ncbi.nlm.nih.gov/pubmed/29866661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-219770
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!